Avantor Faces Securities Fraud Lawsuit Due to Poor Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Performance Decline: Avantor's Q1 2025 financial results missed expectations, causing a 16.6% drop in stock price and a downward revision of guidance, indicating significant impacts from increased competition that harmed investor interests.
- Executive Changes: The announcement of the CEO's resignation raised further concerns about the company's future, leading to a 15.5% decline in stock price following the Q2 2025 earnings report.
- Continued Losses: The Q3 2025 report revealed a net loss of $712 million, primarily due to a $785 million goodwill impairment charge, reflecting a significant decline in profitability under competitive pressures.
- Legal Action: Investors have filed a class action lawsuit alleging that the company failed to disclose its true competitive position during the class period, resulting in substantial losses for investors, with a deadline for participation set for December 29, 2025.
AVTR
$11.43+Infinity%1D
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 13.86 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.280
Low
12.00
Averages
13.86
High
17.00
Current: 11.280
Low
12.00
Averages
13.86
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
